NXC-201 Demonstrates Feasibility of BCMA-Directed CAR T-Cell Therapy in Relapsed/Refractory AL Amyloidosis
NXC-201, a novel anti-BCMA CAR T-cell therapy, showed safety and efficacy in relapsed/refractory AL amyloidosis patients, with a 100% hematologic ORR. However, cardiac disease-related deaths were frequent. CRS occurred in 7 patients, manageable with tocilizumab. The therapy also demonstrated promise in multiple myeloma patients.
Related Clinical Trials
Reference News
NXC-201 Demonstrates Feasibility of BCMA-Directed CAR T-Cell Therapy in Relapsed/Refractory AL Amyloidosis
NXC-201, a novel anti-BCMA CAR T-cell therapy, showed safety and efficacy in relapsed/refractory AL amyloidosis patients, with a 100% hematologic ORR. However, cardiac disease-related deaths were frequent. CRS occurred in 7 patients, manageable with tocilizumab. The therapy also demonstrated promise in multiple myeloma patients.